Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561937 · ClinicalTrials.gov registry record · Phase 1
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT01561937 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 127 participants.
The verdict
NCT01561937, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted INR (International Normalization Ratio).
Interventions
- DRUG placebo
- DRUG warfarin
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561937
The ClinicalTrials.gov registry entry for NCT01561937 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01561937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01561937 about?
NCT01561937 is a clinical study titled "Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment". This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted INR (International Normalization Rati...
What is the current status of trial NCT01561937?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2007-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT01561937?
The interventions under investigation include: placebo (DRUG), warfarin (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT01561937?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.